Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 96,600 shares, a decrease of 65.8% from the August 15th total of 282,600 shares. Currently, 1.9% of the company’s stock are short sold. Based on an average daily trading volume, of 264,700 shares, the short-interest ratio is currently 0.4 days.
Monopar Therapeutics Trading Up 4.3 %
Shares of NASDAQ MNPR traded up $0.02 during mid-day trading on Wednesday, hitting $0.61. The company had a trading volume of 15,897 shares, compared to its average volume of 205,866. The company has a market capitalization of $8.64 million, a PE ratio of -0.77 and a beta of 0.93. The firm has a 50-day simple moving average of $0.72 and a two-hundred day simple moving average of $1.20. Monopar Therapeutics has a one year low of $0.57 and a one year high of $4.88.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Sell-side analysts expect that Monopar Therapeutics will post -0.76 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Monopar Therapeutics
About Monopar Therapeutics
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
- Five stocks we like better than Monopar Therapeutics
- What is a Bond Market Holiday? How to Invest and Trade
- Is Enbridge Stock Too Cheap to Pass Up Now?
- What Are Defense Contractor Stocks? How to Invest in Defense
- 5 Best REIT Alternatives for Passive Real Estate Income
- What Are Growth Stocks and Investing in Them
- 5 Reasons Kroger Should Be On Every Income Investor Watchlist
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.